Skip to content
RDL
Network
Ekosistem
Uygulama değiştir
EN
Hakkımızda
SSS
Giriş yap
Başla
Faculty Opinions recommendation of The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial. — Ralf Weiskirchen | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
Faculty Opinions recommendation of The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial.
RW
Shared by
Ralf Weiskirchen
Faculty Opinions recommendation of The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial.
Dataset
en
Authors
RW
Ralf Weiskirchen
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Related publications
Dataset
Faculty Opinions recommendation of Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis.
Ralf Weiskirchen
Dataset
Faculty Opinions recommendation of Restoration of a healthy intestinal microbiota normalizes portal hypertension in a rat model of nonalcoholic steatohepatitis.
Ralf Weiskirchen
Dataset
Faculty Opinions recommendation of Lipocalin 2 induces neuroinflammation and blood-brain barrier dysfunction through liver-brain axis in murine model of nonalcoholic steatohepatitis.
Ralf Weiskirchen
Dataset
Faculty Opinions recommendation of Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial.
Giuseppe Remuzzi
,
Arrigo Schieppati
Dataset
Faculty Opinions recommendation of Recent Insights into the Pathogenesis of Nonalcoholic Fatty Liver Disease.
Ralf Weiskirchen
Discussion(0)
No comments yet. Be the first to comment.